Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • Life Sciences Transactions

Life Sciences Transactions

Insight | Thought Leadership

Life Sciences Business Evolution Series: Funding Growth and the Future of Life Sciences

Life sciences companies intend to leverage new and existing sources of growth including through M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements as well as avenues tied to corporate PPAs and green financing. Find out about these trajectories as well as continued VC investment and increasing appetite from private equity sponsors in pre-revenue stages.
Read More

Navigating the ever-changing market reality requires responding to growing competition whilst managing cost pressures all while trying to achieve sustainable growth. Get well-rounded advice across 46 jurisdictions from a life sciences transactions team with a keen view of the transactional landscape, industry trends and regulatory outlook.

Explore more below.

Collaborations and Licensing

expand accordion
  • Complex multinational collaborations
  • Joint ventures
  • Commercialization agreements
  • Co-promotion agreements
  • Research and development agreements
  • Evaluation and option agreements

M&A

expand accordion
  • Product acquisitions and divestitures
  • Company sales and acquisitions
  • Business unit spinoffs
  • Post-acquisition integration

Financings

expand accordion
  • Equity financing
  • Royalty monetization
  • Development funding agreements

Operational Agreements

expand accordion
  • Manufacturing and supply agreements
  • Distribution agreements
  • Services agreements
  • University and other nonprofit agreements
Insight | Handbook
Guide to IPOs for Biotech and Pharma Companies
Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.
Insight | Podcast
The Health Pod
The Health Pod, Baker McKenzie's industry podcast series, highlights sector-specific issues and trends that affect healthcare and life sciences companies.
Insight | Handbook
2022 Chambers Advertising & Marketing Practice Guide
This guide provides the latest legal information on comparative advertising, social/digital media, influencer campaigns, cryptocurrency, non-fungible tokens (NFTs) and others.
Insight | Thought Leadership
Data PULSE
Our Data PULSE platform helps you navigate the complex landscape of data, regulatory and IP protection concerns at each stage of the medical product life cycle.
Insight | Handbook
New Chambers Life Sciences Practice Guide 2022
As the global editor, we introduce this year's guide offering commentary on a wide range of legal and business issues in major healthcare and life sciences markets.
Insight | Thought Leadership
Life Sciences Business Evolution Series
Explore how pharma biotech, medical devices and medtech companies plan to evolve their business models, shaping the future of the life sciences ecosystem.
Insight | Recorded Webinar
Healthcare & Life Sciences Supply Chain Series
The Supply Chain Series focuses on the trends, issues and opportunities along each stage of supply chain life cycle for healthcare and life sciences companies.
Insight | Recorded Webinar
Masterclass: Partnering & Licensing
At the LSX Investival Showcase, our lawyers share insights on how biotech companies can navigate licensing issues.  
Insight | Recorded Webinar
Past Healthcare & Life Sciences Webinars
Learn more about the hot topics in the healthcare and life sciences industries.
Insight | Legal Update
Life Sciences Collaborations: Key Considerations in the COVID-19 Era
We present some key considerations that companies in the sector need to bear in mind to cope with the growing complexities of licensing and collaboration agreements.
View All Insight
News | Deal Announcement
Baker McKenzie Client Takeda Enters Worldwide License and Collaboration Agreement for Rusfertide
Rusfertide is currently in trial, VERIFY, for the treatment of Polycythemia Vera, a rare chronic blood disorder. 
News | Deal Announcement
Baker McKenzie Advises Abbott Laboratories in $890 Million Acquisition
Baker McKenzie advised Abbott Laboratories in its acquisition of Cardiovascular Systems, Inc. in an all-cash transaction valued at approximately $890 million.
News | Deal Announcement
Baker McKenzie Advises Wilbur-Ellis in Merger to Form Leading Global Life Sciences and Specialty Chemicals Solutions Distribution Platform with Combined Sales of Approximately EUR 3 Billion
The deal will create a global leader in the life sciences and specialty chemicals solutions sector.
News | Deal Announcement
Baker McKenzie Advised Bristol Myers Squibb in Strategic Collaboration with Amphista Therapeutics
Firm advised Bristol Myers Squibb in a strategic collaboration and license agreement with Amphista.
View All News

Key Resources

Life sciences

Life Sciences Collaborations: Key Considerations in the COVID-19 Era

A high-level guide that outlines a list of issues to consider in executing life sciences collaborations in the COVID-19 era

FT Big Deal Series: The Healthtech Sector’s Spectacular Surge in SPACs and de-SPACS

A three minute video discussing how the pandemic triggered a significant rise in SPAC investments in the healthtech sector.


Flares of different colored light against a black background

Guide to IPOs for Biotech and Pharma Companies

Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.


The Health Pod

Baker McKenzie's industry podcast series that highlights sector-specific issues and trends that affect healthcare & life sciences companies.

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in 5 minutes

How We Can Help

Key Contacts